MIPRAGOSIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C76H137N3O31
Molecular Weight	1588.9025
Optical Activity	UNSPECIFIED
Defined Stereocenters	28 / 28
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O[C@@H]4O[C@H](CO)[C@H](O)[C@H](O)[C@H]4O)[C@H]3NC(C)=O)[C@H](O[C@@]5(C[C@H](O)[C@@H](NC(C)=O)[C@@H](O5)[C@H](O)[C@H](O)CO)C(=O)OC(C)C)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC

InChI

InChIKey=NBMVYETVBIIWFF-AACOHXQBSA-N

InChI=1S/C76H137N3O31/c1-7-9-11-13-15-17-19-21-22-24-26-28-30-32-34-36-55(90)79-47(48(87)35-33-31-29-27-25-23-20-18-16-14-12-10-8-2)43-100-72-64(97)62(95)66(53(41-83)104-72)106-74-65(98)70(110-76(75(99)101-44(3)4)37-49(88)56(77-45(5)85)69(109-76)58(91)50(89)38-80)67(54(42-84)105-74)107-71-57(78-46(6)86)68(60(93)52(40-82)102-71)108-73-63(96)61(94)59(92)51(39-81)103-73/h33,35,44,47-54,56-74,80-84,87-89,91-98H,7-32,34,36-43H2,1-6H3,(H,77,85)(H,78,86)(H,79,90)/b35-33+/t47-,48+,49-,50+,51+,52+,53+,54+,56+,57+,58+,59-,60-,61-,62+,63+,64+,65+,66+,67-,68+,69+,70+,71-,72+,73-,74-,76-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C76H137N3O31
Molecular Weight	1588.9025
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	28 / 28
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8944090 | https://adisinsight.springer.com/drugs/800003994

Mipragoside (also known as AGF 44), an isopropyl ester of monosialoganglioside GM1 that was developed as an anti-inflammatory agent. The topical treatment by this drug improved symptoms of patients with vernal keratoconjunctivitis. Mipragoside was in phase I in Italy for the treatment of inflammation; however, this study was discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Efficacy of mipragoside ophthalmic gel in vernal keratoconjunctivitis.	1996	8944090
Anti-inflammatory action of AGF44, a ganglioside ester derivative.	1992	1478165

Sample Use Guides

In Vivo Use Guide

Patients received either Mipragoside 0.5% aqueous ophthalmic gel or placebo four times a day for 2 weeks after a week of treatment with placebo.

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:07:44 GMT 2025` Edited by `admin` on `Mon Mar 31 18:07:44 GMT 2025`
Record UNII	IOR159KL0H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AGF 44

Preferred Name

English

MIPRAGOSIDE

Official Name

English

mipragoside [INN]

Common Name

English

N-(II(SUP 3)-N-ACETYLNEURAMINOSYLGANGLIOTETRAOSYL)CERAMIDE, ISOPROPYL ESTER

Common Name

English

Code System Code Type Description

SMS_ID

100000080643